SLC5A2 and heart failure: The benefits of SGLT2 inhibitors observed in patients with heart failure across a wide spectrum of LVEF, diabetes status, baseline functional status, and age group[5–7,9] suggest its wide and continuously expanding clinical indication and marks a significant achievement in cardiovascular medicine.